Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

M701 pleural infusion

Preclinical

WWuhan YZY Biopharma Co., Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Malignant Pleural EffusionsRecruiting

Malignant Pleural EffusionsPreclinical

Recruiting

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Malignant Pleural Effusions

NCT05543330

Clinical

Trials by Indication[1]

Malignant Pleural Effusions1 trial

A Phase 1, Multicenter, Open-label, Dose-increasing Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of M701, a Recombinant Epcam and CD3 Bispecific Antibody , in Patients With Malignant Pleural Effusions Caused by NSCLC

Recruiting·WWuhan YZY Biopharma Co., Ltd.·Preclinical·NCT05543330·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for M701 pleural infusion. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for M701 pleural infusion. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Wuhan YZY Biopharma Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: WWuhan YZY Biopharma Co., Ltd.

Related News